This medicinal product is for diagnostic use only.GHRH is applied to determine the somatotropic function of the anterior pituitary gland in cases of suspected growth hormone deficiency. The test distinguishes between pituitary and hypothalamic disorders but is not suitable as a screening test for growth hormone deficiencies.The diluent is supplied for the reconstitution of an injectable preparation.
Ferring has licensed from Albireo the world rights to elobixibat, excluding those territories held by Ajimoto. Elobixibat is a first-in-class...
Ferring Pharmaceuticals announced that it has signed an agreement with Seikagaku Corporation granting Ferring the exclusive worldwide rights (excluding Japan)...
Ferring Pharmaceuticals and Merck Inc., through its Merck for Mothers initiative, announced the completion of CHAMPION (Carbetocin Haemorrhage Prevention), a...
Ferring Pharmaceuticals and Rebiotix Inc. announce that they have agreed to the acquisition of Rebiotix by Ferring. This acquisition brings...
Ferring Pharmaceuticals has announced the positive outcome of the European Decentralised Procedure (DCP) for Testavan (transdermal testosterone gel 2%), a...
NICE has issued new draft guidance recommending Firmagon (degarelix), from Ferring Pharmaceuticals, as an option for treating Prostate Cancer in...
Ferring Pharmaceuticals and Blackstone Life Sciences announced the joint investment of over $570 million USD in nadofaragene firadenovec (rAd-IFN/Syn3), an...
UCB and Ferring Pharmaceuticals Inc. announced they have entered into a co-promotion agreement to commercialize the prefilled syringe formulation of Cimzia (certolizumab pegol) in the United States, specifically for the treatment of Crohn’s disease (CD).
Ferring Pharmaceuticals announced that the FDA has approved an expanded indication for Zomacton (somatropin) for Injection 5 mg and 10...